Shots: The approval is based on results of P-III ADMIRAL trial assessing Xospata (120 mg,qd ) vs salvage CT in ≥371 patients in ratio (2:1) with FLT3 mutations who are refractory to or have relapsed after 1L AML therapy P-III ADMIRAL trial results: CR/CRh 21%, median duration of CR/CRh 4.6 mos., rate of conversion from […]Read More
